The Federal Court of Appeals has upheld Sigma Lithium's environmental licenses, allowing the company to fully resume its mining and industrial operations. This legal victory strengthens confidence in Sigma Lithium's plan to produce 330,000 tonnes of lithium oxide concentrate annually by the end of 2027, using existing mine and processing capacity. The court recognized Sigma Lithium's significant economic impact in the Vale do Jequitinhonha region, where it supports around 19,000 jobs and benefits approximately 80,000 family members. The company also drives social and economic development through various community programs, contributing to substantial GDP growth in local municipalities. This decision follows the overturning of a local emergency ruling that had temporarily suspended the licenses, and it aligns with favorable political developments supporting the lithium industry in Minas Gerais, Brazil.
Sigma Lithium's mining and industrial operations status is presented here with Pluang's Basic Materials sector data as of Oct 07, 2026 03:12 WIB. Among 38 priced US stocks in this sector, 27 rose and 10 fell today. Notable movers include MP Materials at USD 48.54 with a 3.63% increase and a typical hold time of 10 days, and Vale SA at USD 14.22 with a 3.34% rise and a typical hold time of 109 days.
Constellation Brands reported earnings per share of $3.74, surpassing analyst estimates of $3.55, and revenue of $2.63 billion, exceeding the $2.54 billion forecast. The company saw a 5% increase in beer sales and a 17% rise in wine and spirits sales...
Tilray Brands will announce its fiscal Q1 2027 earnings on October 8, with analysts forecasting a loss of $0.16-$0.19 per share on revenues around $265-$268 million, marking about 26% growth from last year. Investors will focus on cannabis and bevera...
On October 6, 2026, five notable stocks surged between 20.9% and 52.7%, driven by various positive developments. Apimeds Pharmaceuticals rose 52.7% after its subsidiary signed a blockchain contract, while Option Care Health gained 32.7% following a $...
On October 6, five notable stocks saw significant declines, with losses ranging from 17.5% to 50.1%. ArriVent BioPharma's shares plunged 46.9% after its lung cancer treatment failed to meet the primary endpoint in a Phase 3 trial. Armada Acquisition ...
Evercore ISI raised its price target for Marvell Technology to $433 from $275, maintaining an Outperform rating. This follows Marvell's optimistic revenue projections, expecting $20 billion by fiscal 2028 and $70-$90 billion by fiscal 2031, driven by...
